BioPharmSignal logoBioPharmSignal

Biotech News

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

Candel Therapeutics (CADL)Candel TherapeuticsConference / presentation

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking

Related news

CADLCandel Therapeutics2026-11-06 14:00 EST

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

CADLCandel Therapeutics2026-09-30 12:30 EST

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

View all latest news

Candel Therapeutics

Multimodal Cancer Immunotherapy Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response. Aglatimagene Besadenovec Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into...

Recent company news

CADLCandel Therapeutics2026-11-06 14:00 EST

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

CADLCandel Therapeutics2026-11-05 21:06 EST

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-11-02 21:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-10-29 13:00 EST

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

CADLCandel Therapeutics2026-10-27 12:05 EST

Candel Therapeutics to Present at November Investor Conferences

Stock data

Close
8.04 USD
Market cap
616.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States